[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Q32 Bio Inc (QTTB)

Q32 Bio Inc (QTTB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Q32 Bio: Q2 Earnings Snapshot

Q32 Bio: Q2 Earnings Snapshot

QTTB : 15.15 (-1.43%)
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

-- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at...

QTTB : 15.15 (-1.43%)
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

WALTHAM, Mass. , July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other...

QTTB : 15.15 (-1.43%)
Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

WALTHAM, Mass. , July 13, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA")...

QTTB : 15.15 (-1.43%)
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata

-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis --

QTTB : 15.15 (-1.43%)
Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026

-- Conference call to be held Monday, July 13 th at 8:00 a.m. E.T. --

QTTB : 15.15 (-1.43%)
Q32 Bio Announces $55 Million Private Placement Financing

WALTHAM, Mass. , May 27, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia...

QTTB : 15.15 (-1.43%)
Q32 Bio: Q1 Earnings Snapshot

Q32 Bio: Q1 Earnings Snapshot

QTTB : 15.15 (-1.43%)
Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

-- Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a clinical trial on-track for mid-2026 --

QTTB : 15.15 (-1.43%)
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

WALTHAM, Mass. , April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA)...

QTTB : 15.15 (-1.43%)

Barchart Exclusives

Dear Reddit Stock Fans, Mark Your Calendars for August 18
Reddit stock rallies ahead of inclusion in the S&P 500 index on August 18. Here’s why the announcement makes RDDT shares worth owning. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.